New combo therapy tested for tough-to-treat hodgkin lymphoma
NCT ID NCT02227199
Summary
This study tested a combination of a targeted cancer drug (brentuximab vedotin) with three standard chemotherapy drugs for patients whose Hodgkin lymphoma had returned or wasn't responding to treatment. The goal was to find the safest, most effective dose and see how well this combination worked to control the cancer. The treatment was designed to prepare patients for a possible stem cell transplant, which is a common next step for this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.